Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23081899 | 0.91 | RIPK1 (0.49) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL23076327 | 0.83 | RIPK1 (0.48) | NPC1RAB9ARIPK1GRM5 | |
| SCHEMBL23075920 | 0.83 | RIPK1 (0.48) | RIPK1GRM5 | |
| SCHEMBL25586411 | 0.82 | GRM5 (0.40) | RIPK1GRM5 | |
| SCHEMBL23900311 | 0.81 | GRM5 (0.51) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL25584836 | 0.81 | RIPK1 (0.47) | RIPK1GRM5 | |
| SCHEMBL30387134 | 0.81 | RIPK1 (0.47) | RIPK1GRM5 | |
| SCHEMBL25584909 | 0.81 | MAP3K14 (0.38) | NPC1RAB9ARIPK1GRM5 | |
| SCHEMBL24076721 | 0.80 | RIPK1 (0.56) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL25587259 | 0.78 | NPC1 (0.47) | NPC1HCRTR1RAB9APOLBPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | NPC1 2143/4885HCRTR1 2933/4885RAB9A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.